North America Pharmacogenetic Testing Market to 2032
Overview
The North America Pharmacogenetic Testing Market is expected to reach a 6.31 USD Billion by 2032 and is projected to grow at a CAGR of 12.74% from 2025 to 2032.
Revenue, 2024 (USD Billion)
3.16
Forecast, 2032 (USD Billion)
6.31
CAGR, 2024 - 2032
12.74%
Report Coverage
North America
North America Pharmacogenetic Testing Market 2018-2032 USD Billion
North America Pharmacogenetic Testing Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 3.16 USD Billion
- Projected Market Size (2032): 6.31 USD Billion
- CAGR (2025-2032): 12.74%
Key Findings of North America Pharmacogenetic Testing Market
- The North America Pharmacogenetic Testing Market was valued at 3.16 USD Billion in 2024.
- The North America Pharmacogenetic Testing Market is likely to grow at a CAGR of 12.74% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Blood in Sample Segment accounted for the largest share of the market with a revenue of 1.69 USD Billion
- The fastest growing segment CYP2C19 in Gene Segment grew Fastest with a CAGR of 17.32% during the forecast period from 2024 to 2032.
North America Pharmacogenetic Testing Market Scope
North America Pharmacogenetic Testing Market Segmentation & Scope
Type
- Single Gene Tests
- Array-Based Tests
- Whole Exome Sequencing
- Whole Genome Sequencing
Distribution Channel
- Direct-to-Customer Services
- Mail-Order Pharmacies
- Retail Pharmacies
- Hospital Pharmacy
End User
- Others
- Research Centres and Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Healthcare Providers
Application
- Drug Regulation
- Drug Development
- Clinical Practice
Gene
- Others
- TMPT
- HTR2A/C
- SLC6A4
- D4D4
- DRD3
- ONCOTYPE DX® AND MAMMAPRINT®
- OPRM1
- CYP2D
- HLA-B*5701
- HLA-B*1502
- CYP1A2
- CYP2C9 AND VKORC1
- CYP2D6
- CYP2C19
Drug
- Over-the-Counter Medications
- Vitamins
- Herbal Supplements
- Recreational Drugs
- Nutraceuticals
- Prescription Drugs
Therapeutic Area
- Others
- Neurology
- Oncology
- Gynecology
- Dermatology
- Immunology & Hypersensitivity
- Endocrinology
- Genomics
- Anesthesiology
- Gastroenterology
- Cardiology
Sample
- Saliva
- Blood
North America Pharmacogenetic Testing Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 3.16 USD Billion |
| Market Value in 2032 | 6.31 USD Billion |
| CAGR (2025-2032) | 12.74% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Type,Distribution Channel,End User,Application,Gene,Drug,Therapeutic Area,Sample |
Regional Insights:
-
Leading Market (2024-2032): North America, leading in terms of revenue 3.16 USD Billion in 2024
- Key Country: U.S., leading in terms of revenue with value of 1,430.72 USD Million in 2024.
Segments and Scope
-
North America Pharmacogenetic Testing Market to 2032, By Type
- Whole Genome Sequencing is the largest segment in North America Pharmacogenetic Testing Market to 2032 with a revenue of 1.48 USD Billion in the year 2024.
- Whole Genome Sequencing is the Fastest growing segment in North America Pharmacogenetic Testing Market to 2032 with a Growth rate of 13.46 % in forecast period 2025-2032.
-
North America Pharmacogenetic Testing Market to 2032, By Distribution Channel
- Hospital Pharmacy is the largest segment in North America Pharmacogenetic Testing Market to 2032 with a revenue of 1.41 USD Billion in the year 2024.
- Hospital Pharmacy is the Fastest growing segment in North America Pharmacogenetic Testing Market to 2032 with a Growth rate of 13.46 % in forecast period 2025-2032.
-
North America Pharmacogenetic Testing Market to 2032, By End User
- Healthcare Providers is the largest segment in North America Pharmacogenetic Testing Market to 2032 with a revenue of 1.24 USD Billion in the year 2024.
- Healthcare Providers is the Fastest growing segment in North America Pharmacogenetic Testing Market to 2032 with a Growth rate of 13.63 % in forecast period 2025-2032.
-
North America Pharmacogenetic Testing Market to 2032, By Application
- Clinical Practice is the largest segment in North America Pharmacogenetic Testing Market to 2032 with a revenue of 1.39 USD Billion in the year 2024.
- Clinical Practice is the Fastest growing segment in North America Pharmacogenetic Testing Market to 2032 with a Growth rate of 13.42 % in forecast period 2025-2032.
-
North America Pharmacogenetic Testing Market to 2032, By Gene
- CYP2C19 is the largest segment in North America Pharmacogenetic Testing Market to 2032 with a revenue of 551.03 USD Billion in the year 2024.
- CYP2C19 is the Fastest growing segment in North America Pharmacogenetic Testing Market to 2032 with a Growth rate of 17.32 % in forecast period 2025-2032.
-
North America Pharmacogenetic Testing Market to 2032, By Drug
- Prescription Drugs is the largest segment in North America Pharmacogenetic Testing Market to 2032 with a revenue of 976.70 USD Billion in the year 2024.
- Prescription Drugs is the Fastest growing segment in North America Pharmacogenetic Testing Market to 2032 with a Growth rate of 14.66 % in forecast period 2025-2032.
-
North America Pharmacogenetic Testing Market to 2032, By Therapeutic Area
- Cardiology is the largest segment in North America Pharmacogenetic Testing Market to 2032 with a revenue of 634.26 USD Billion in the year 2024.
- Cardiology is the Fastest growing segment in North America Pharmacogenetic Testing Market to 2032 with a Growth rate of 17.06 % in forecast period 2025-2032.
-
North America Pharmacogenetic Testing Market to 2032, By Sample
- Blood is the largest segment in North America Pharmacogenetic Testing Market to 2032 with a revenue of 1.69 USD Billion in the year 2024.
- Blood is the Fastest growing segment in North America Pharmacogenetic Testing Market to 2032 with a Growth rate of 12.95 % in forecast period 2025-2032.
North America Pharmacogenetic Testing Market Company Share Analysis
| Company Name |
|
||
| Illumina, Inc. | |||
| Thermo Fisher Scientific Inc. | |||
| QIAGEN | |||
| Sonic Healthcare Limited | |||
| BGI | |||
North America Pharmacogenetic Testing Market Geographical Sales Distribution, 2018-2032 USD Billion
North America Pharmacogenetic Testing Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The North America Pharmacogenetic Testing Market is segmented based on Segmentation Type,Distribution Channel,End User,Application,Gene,Drug,Therapeutic Area,Sample.
North America Pharmacogenetic Testing Market was valued at USD 3.16(Revenue in USD Billion) in 2021.
North America Pharmacogenetic Testing Market is projected to grow at a CAGR of 12.74% during the forecast period of 2024 to 2032.
The Blood segment is expected to dominate the North America Pharmacogenetic Testing Market, holding a largest market share of 1.69 USD Billion in 2024
North America Pharmacogenetic Testing Market Scope
North America Pharmacogenetic Testing Market Segmentation & Scope
Type
- Single Gene Tests
- Array-Based Tests
- Whole Exome Sequencing
- Whole Genome Sequencing
Distribution Channel
- Direct-to-Customer Services
- Mail-Order Pharmacies
- Retail Pharmacies
- Hospital Pharmacy
End User
- Others
- Research Centres and Academic Institutes
- Pharmaceutical & Biotechnology Companies
- Healthcare Providers
Application
- Drug Regulation
- Drug Development
- Clinical Practice
Gene
- Others
- TMPT
- HTR2A/C
- SLC6A4
- D4D4
- DRD3
- ONCOTYPE DX® AND MAMMAPRINT®
- OPRM1
- CYP2D
- HLA-B*5701
- HLA-B*1502
- CYP1A2
- CYP2C9 AND VKORC1
- CYP2D6
- CYP2C19
Drug
- Over-the-Counter Medications
- Vitamins
- Herbal Supplements
- Recreational Drugs
- Nutraceuticals
- Prescription Drugs
Therapeutic Area
- Others
- Neurology
- Oncology
- Gynecology
- Dermatology
- Immunology & Hypersensitivity
- Endocrinology
- Genomics
- Anesthesiology
- Gastroenterology
- Cardiology
Sample
- Saliva
- Blood
Frequently Asked Questions
The North America Pharmacogenetic Testing Market is segmented based on Segmentation Type,Distribution Channel,End User,Application,Gene,Drug,Therapeutic Area,Sample.
North America Pharmacogenetic Testing Market was valued at USD 3.16(Revenue in USD Billion) in 2021.
North America Pharmacogenetic Testing Market is projected to grow at a CAGR of 12.74% during the forecast period of 2024 to 2032.
The estimated market value of the North America Pharmacogenetic Testing Market for final year is USD 6.31 (USD Billion).
North America Pharmacogenetic Testing Market Company Profiling
Frequently Asked Questions
The North America Pharmacogenetic Testing Market is segmented based on Segmentation Type,Distribution Channel,End User,Application,Gene,Drug,Therapeutic Area,Sample.
North America Pharmacogenetic Testing Market was valued at USD 3.16(Revenue in USD Billion) in 2021.
North America Pharmacogenetic Testing Market is projected to grow at a CAGR of 12.74% during the forecast period of 2024 to 2032.
The estimated market value of the North America Pharmacogenetic Testing Market for final year is USD 6.31 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.